Trade Sarepta Therapeutics, Inc. - SRPT CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.67 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 107.82 |
| Open | 108.48 |
| 1-Year Change | -20.21% |
| Day's Range | 106.06 - 108.6 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 106.06 | -3.02 | -2.77% | 109.08 | 109.08 | 105.59 |
| Feb 20, 2025 | 107.82 | 0.66 | 0.62% | 107.16 | 109.73 | 105.85 |
| Feb 19, 2025 | 106.53 | 1.23 | 1.17% | 105.30 | 107.24 | 104.50 |
| Feb 18, 2025 | 104.69 | 1.77 | 1.72% | 102.92 | 105.95 | 100.70 |
| Feb 14, 2025 | 107.42 | -1.94 | -1.77% | 109.36 | 110.74 | 107.28 |
| Feb 13, 2025 | 108.72 | -0.44 | -0.40% | 109.16 | 109.93 | 107.60 |
| Feb 12, 2025 | 109.67 | 1.72 | 1.59% | 107.95 | 110.12 | 107.95 |
| Feb 11, 2025 | 109.46 | -0.96 | -0.87% | 110.42 | 111.30 | 109.25 |
| Feb 10, 2025 | 112.60 | 0.85 | 0.76% | 111.75 | 114.20 | 110.01 |
| Feb 7, 2025 | 111.05 | -0.66 | -0.59% | 111.71 | 111.92 | 109.11 |
| Feb 6, 2025 | 111.96 | -6.16 | -5.22% | 118.12 | 118.55 | 111.61 |
| Feb 5, 2025 | 118.95 | 4.91 | 4.31% | 114.04 | 119.83 | 113.24 |
| Feb 4, 2025 | 113.88 | 0.82 | 0.73% | 113.06 | 114.80 | 112.82 |
| Feb 3, 2025 | 113.20 | 2.03 | 1.83% | 111.17 | 114.55 | 111.17 |
| Jan 31, 2025 | 113.35 | -0.47 | -0.41% | 113.82 | 115.82 | 112.44 |
| Jan 30, 2025 | 114.36 | -1.23 | -1.06% | 115.59 | 116.18 | 113.25 |
| Jan 29, 2025 | 114.86 | -2.17 | -1.85% | 117.03 | 117.03 | 113.07 |
| Jan 28, 2025 | 117.23 | 0.44 | 0.38% | 116.79 | 118.02 | 116.33 |
| Jan 27, 2025 | 116.34 | 0.31 | 0.27% | 116.03 | 119.34 | 115.35 |
| Jan 24, 2025 | 116.30 | -2.59 | -2.18% | 118.89 | 118.89 | 115.41 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Sarepta Company profile
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also provides Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company provides SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA resulting in exclusion of exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. The company has strategic alliances with Nationwide Children's Hospital for the advancement of micro-dystrophin gene therapy program under the research and license option agreement, as well as Galgt2 gene therapy program under the license agreement; and Genethon for the advancement of micro-dystrophin gene therapy program under a research and exclusive license option agreement. It also has a research and license option agreement with Duke University for the advancement of gene editing CRISPR/Cas9 technology for muscular dystrophy; and a collaboration and license agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States, as well as through distributors internationally. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.| Industry: | Bio Therapeutic Drugs |
215 1st St Ste 415
CAMBRIDGE
MASSACHUSETTS 02142-1213
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com